Intellia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Intellia Therapeutics (NTLA).

Price Target Range — 11 Quarters

Analyst Consensus — 24 Analysts

2S.Buy

13Buy

5Hold

4Sell

Consensus RatingBuy# Analysts24Avg. Consensus PT$25Upside to Avg. PT+117.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Barclays	Eliana Merle	Initiate	Underweight	$8
Sep 9, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$30
Sep 9, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$12→$13
Sep 9, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
Aug 25, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$30
Aug 7, 2026	Evercore ISI Group	Jonathan Miller	Upgrade	In-Line→Outperform	$16→$24
Jul 16, 2026	Wolfe Research	Andy Chen	Downgrade	Peer Perform→Underperform	$9
Jul 10, 2026	Wedbush	David Nierengarten	PT Raise	Neutral	$12→$17
Jun 16, 2026	Canaccord Genuity	Whitney Ijem	Maintained	Buy	$49
Jun 15, 2026	Citizens	Silvan Turkcan	Maintained	Market Outperform	$30
Jun 15, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$12
Jun 15, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	Maintained	Buy	$25
May 13, 2026	Bernstein	William Pickering	PT Raise	Market Perform	$13→$17
May 13, 2026	HC Wainwright & Co.	Mitchell S. Kapoor	PT Cut	Buy	$30→$25
May 12, 2026	Canaccord Genuity	Whitney Ijem	PT Cut	Buy	$58→$49
May 12, 2026	Wedbush	David Nierengarten	Maintained	Neutral	$12
Apr 28, 2026	Canaccord Genuity	Whitney Ijem	PT Raise	Buy	$48→$58
Apr 28, 2026	Goldman Sachs	Salveen Richter	PT Raise	Sell	$8→$9
Apr 28, 2026	Morgan Stanley	Terence Flynn	PT Raise	Equal-Weight	$11→$15
Apr 28, 2026	Citizens	Silvan Turkcan	PT Raise	Market Outperform	$28→$30

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.

Benzinga Newsdesk

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

Wedbush analyst David Nierengarten maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and raises the price target from $12 to $13.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.

Benzinga Newsdesk

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.

Benzinga Newsdesk

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

Evercore ISI Group analyst Jonathan Miller upgrades Intellia Therapeutics (NASDAQ:NTLA) from In-Line to Outperform and raises the price target from $16 to $24.

Benzinga Newsdesk

Intellia Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Intellia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

PRO
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

People Also Watch

People Also Watch

Intellia Therapeutics Inc

뉴스

파트너 / 기고자

벤징가 글로벌

Intellia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBarclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

PROCitizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PROWedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

PROHC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

PROCitizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PROEvercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24

People Also Watch

People Also Watch

PRO
Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Wedbush Maintains Neutral on Intellia Therapeutics, Raises Price Target to $13

PRO
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

PRO
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

PRO
Evercore ISI Group Upgrades Intellia Therapeutics to Outperform, Raises Price Target to $24